Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

about

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Item

http://www.wikidata.org/entity/Q52689208

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

@en

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

@nl

type

Item

label

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

@en

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

@nl

prefLabel

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

@en

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

@nl

P1476

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis

@en

P2093

Ahmet Dogan

http://www.w3.org/2001/XMLSchema#string

Ankush Bhatia

http://www.w3.org/2001/XMLSchema#string

Chezi Ganzel

http://www.w3.org/2001/XMLSchema#string

David M Hyman

http://www.w3.org/2001/XMLSchema#string

Eli L Diamond

http://www.w3.org/2001/XMLSchema#string

Gary Ulaner

http://www.w3.org/2001/XMLSchema#string

Julio Hajdenberg

http://www.w3.org/2001/XMLSchema#string

Mario E Lacouture

http://www.w3.org/2001/XMLSchema#string

Neval Ozkaya

http://www.w3.org/2001/XMLSchema#string

Omar Abdel-Wahab

http://www.w3.org/2001/XMLSchema#string

P2860

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Dabrafenib and its potential for the treatment of metastatic melanoma.

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA.

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.

P304

e177-e180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2017.185298

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin Durham

P577

2018-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29472347

http://www.w3.org/2001/XMLSchema#string

P932

5865413

http://www.w3.org/2001/XMLSchema#string